Immuron Ltd has released a press release.
Appendix 4E and 2020 Financial Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Immuron
- Immuron Announces US$20.0 Million Registered Direct Offering
- Immuron Reports Neutralizing activity Against SARS-CoV-2
- US DoD Receives FDA Guidance on clinical development plans
- IMC & CSIRO to produce oral therapeutic for DoD evaluation
- Response to ASX Price Query
Later from Immuron
- Immuron Travelers Diarrhea Market Update
- US DoD NMRC Reports Positive Response to Vaccine
- Immuron Receives AUD $358,280 R&D Tax Concession Refund
- Immuron SARS-CoV-2 Research Agreement with Monash University
- IMM124E May Offer New Modality for Inhibition of SARS-CoV-2
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron